key: cord-0814809-cfhoi754
authors: Deocleciano de Araujo, Clara; Schlittler, Leandro X.C.; Sguario, Rodrigo Mantovani; Tsukumo, Daniela Miti; Dalgalarrondo, Paulo; Banzato, Claudio E.M.
title: Life-threatening catatonia associated with COVID-19
date: 2020-10-22
journal: Psychosomatics
DOI: 10.1016/j.psym.2020.09.007
sha: 97ebbdaa779b64ca84d649c8604dc689f1dfdcd6
doc_id: 814809
cord_uid: cfhoi754

nan

The first reported case of catatonia associated with Covid-19 was recently published by Caan et al. (2020) 1 . The patient was a 43-year-old man, without psychiatric history, who sought medical care for headache and fever. Though probable diagnosis was Covid-19, the confirmation came after several visits to the emergency department with other complaints, physical (back pain, spasm, coughing) and mental/behavioral (insomnia and anxiety related to the concern with Covid-19 and later on talking to himself, not drinking, eating or showering).

Catatonia was diagnosed during the third day of hospitalization, 18 days after initial symptoms, and was successfully treated with lorazepam (intravenous at first, then oral).

We present another case of catatonia and COVID-19 association that has some similarities but also significant differences, which make it worth reporting. In our case, the patient became critically ill, receiving intensive care, and his malignant catatonia 2 only resolved after electroconvulsive therapy (ECT).

Case: A 50-year-old man with a mild intellectual disability was admitted in a catatonic stupor. Since the previous week, he had shown grossly disorganized behavior and marked social withdrawal, which evolved with reduced motricity, severe body stiffness, negativism, urinating and defecating in clothes, and refusal to feed and weight loss.

Two weeks before the initial symptoms, a friend from the workplace had committed suicide. Five days before admission, one of his brothers hanged himself, but he remained unaware of this fact. He had epilepsy treated with phenobarbital from childhood until adolescence (last seizure at 18 yo). His deceased mother had late-onset bipolar affective disorder followed by dementia, and a sister has a depressive disorder.

At investigation, main findings were: normal brain CT, light increased CSF protein (55 mg/dL), high creatine kinase (8,819 U/l), leukocytosis (20,800 mm³/L), and high platelet count (544,000 mm³/L). Intravenous hydration, electrolytic replacement, prophylactic anticoagulation, and diazepam 10 mg iv q.i.d were started.

On day two, he presented tachypnea (26 bpm), tachycardia (122 bpm), and COVID-19 was diagnosed by RT-PCR. The family denied previous respiratory symptoms. Chest CT showed predominantly reticulated thin small opacities in frosted glass, with peripheral distribution in lateral and posterior lower lobes.

On day three, he presented fever (38.8ºC) and hypoxia (O 2 sat= 91%). Nasal cannula oxygen therapy (6 L/min) and dexamethasone 6mg q.d. were started. The next day, azithromycin 500 mg q.d. and amoxicillin/clavulanate 1g t.i.d were added. After four days, oral lorazepam 2 mg t.i.d was substituted for intravenous diazepam. On day six, because of J o u r n a l P r e -p r o o f bacteremia signs, piperacillin/tazobactam was started. Despite benzodiazepines, stiffness and diaphoresis remained extreme, and the patient persisted in critical conditions. From day 10 to day 18, fever persisted. Aspiration pneumonia was diagnosed on day 13, treated with meropenem and vancomycin.

As severe catatonia persisted and clinical instability prevented ECT, low doses of sertraline (25 mg p.o. q.d.) and olanzapine (5 mg p.o. q.d.) were tentatively initiated.

On day 19, the patient was transferred from intensive care to the psychiatric unit, and finally, ECT with bilateral stimulus 30% was started. He showed a partial response, starting to say a few words, and showing light improvement in stiffness. From the third ECT session on, he was able to engage in a conversation when prompted and showed marked improvement in stiffness. His recovery progressed gradually, and after the 5th ECT session, the enteral tube was removed; after the sixth session, the patient was able to stand up. From the seventh session on, he was able to walk by himself with some difficulty.

After ten ECT sessions, the catatonic syndrome improved substantially. However, the patient was unable to recall anything that happened during admission and the weeks before.

The patient was discharged after 50 days of admission, fully recovered, with a prescription of olanzapine and sertraline. At discharge, according to his family, he was back to his usual self. He denied depressive symptoms prior to catatonia and was not upset about these events. He did not present affective or psychotic symptoms and reported feeling ready to resume his life.

In these challenging times of COVID-19 pandemics, an important lesson can be learned from this case: the value of close cooperation between internal medicine and psychiatry teams to attend the multiple needs of patients in which severe psychiatric and clinical manifestations intertwine.

A Case of Catatonia in a Man With COVID-19

Malignant catatonia warrants early psychiatriccritical care collaborative management: two cases and literature review. Case Rep Crit Care